Table 5.
Documented treatment with clozapine lifetime.
| Variables | N | Clozapine treatment lifetime (N = 68) | No documented clozapine treatment lifetime (N = 263) | t/Χ² | df | p |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age at time of LP | 68/263 | 38.75 ± 17.45 | 37.40 ± 15.08 | 0.586 | 94.48 | 0.559a |
| Duration of illness (months) | 66/211 | 123.53 ± 135.98 | 55.82 ± 83.74 | 3.83 | 80.98 | <0.001a |
| Age at onset of disease (years) | 65/229 | 28.94 ± 12.63 | 33.64 ± 13.87 | −2.456 | 292 | 0.015a |
| Gender (f/m) | 331 | 29/39 | 114/149 | 0.011 | 1 | 0.917b |
| CSF parameter | ||||||
| Protein level (mg/dl) | 328 | 41.45(N = 68)± 17.26 | 38.13(N = 260)± 14.30 | 1.63 | 326 | 0.104a |
| Protein level elevated (yes/no) | 328 | 19/49 | 46/214 | 3.56 | 1 | 0.059b |
| Albumin ratio | 330 | 6.37(N = 68) ± 3.05 | 5.72(N = 262) ± 2.48 | 1.81 | 328 | 0.071a |
| Albumin ratio elevated (yes/no) | 330 | 22/46 | 75/187 | 0.361 | 1 | 0.548b |
| White blood cell count (cells/µl) | 329 | 1.72(N = 68) ±1.91 | 1.52(N = 261)±1.77 | 0.839 | 327 | 0.402a |
| Pleocytosis (> 4/µl) (yes/no) | 329 | 7/61 | 13/248 | 2.667 | 1 | 0.102b |
| Pleocytosis (> 5/µl) (yes/no) | 329 | 4/64 | 8/253 | 0.279c | ||
| Pleocytosis (> 6/µl) (yes/no) | 329 | 3/65 | 5/256 | 0.369c | ||
| OCB (yes/no) | 329 | 24/44 | 98/163 | 0.117 | 1 | 0.732b |
| OCB intrathecal synthesis (yes/no) | 122 | 10/14 | 29/69 | 1.292 | 1 | 0.256b |
aIndependent t test.
bX² test.
cFisher’s exact test (two-sided) was used in case n < 5 in a 2 × 2 table.
CSF cerebrospinal fluid, f female, LP lumbar puncture, m male, OCB oligoclonal bands.